Your browser doesn't support javascript.
loading
Neutralizing immunity in vaccine breakthrough infections from the SARS-CoV-2 Omicron and Delta variants
Venice Servellita; Abdullah M Syed; Noah Brazer; Prachi Saldhi; Miguel Garcia-Knight; Bharath Sreekumar; Mir M Khalid; Alison Ciling; Pei-Yi Chen; G. Renuka Kumar; Amelia S Gliwa; Jenny Nguyen; Alicia Sotomayor-Gonzalez; Yueyuan Zhang; Edwin Frias; John Prostko; John Hackett; Raul Andino; Jennifer Doudna; Melanie Ott; Charles Y Chiu.
Afiliação
  • Venice Servellita; University of California, San Francisco
  • Abdullah M Syed; University of California, San Francisco
  • Noah Brazer; University of California, San Francisco
  • Prachi Saldhi; University of California, San Francisco
  • Miguel Garcia-Knight; University of California, San Francisco
  • Bharath Sreekumar; University of California, San Francisco
  • Mir M Khalid; University of California, San Francisco
  • Alison Ciling; University of California, San Francisco
  • Pei-Yi Chen; University of California, San Francisco
  • G. Renuka Kumar; University of California, San Francisco
  • Amelia S Gliwa; University of California, San Francisco
  • Jenny Nguyen; University of California, San Francisco
  • Alicia Sotomayor-Gonzalez; University of California, San Francisco
  • Yueyuan Zhang; University of California, San Francisco
  • Edwin Frias; Abbott Laboratories
  • John Prostko; Abbott Laboratories
  • John Hackett; Abbott Laboratories
  • Raul Andino; University of California, San Francisco
  • Jennifer Doudna; University of California, Berkeley
  • Melanie Ott; University of California, San Francisco
  • Charles Y Chiu; University of California, San Francisco
Preprint em En | PREPRINT-MEDRXIV | ID: ppmedrxiv-22269794
ABSTRACT
Virus-like particle (VLP) and live virus assays were used to investigate neutralizing immunity to Delta and Omicron SARS-CoV-2 variants in 239 samples from 125 fully vaccinated individuals. In uninfected, non-boosted individuals, VLP neutralization titers to Delta and Omicron were reduced 2.7-fold and 15.4-fold, respectively, compared to wild-type (WT), while boosted individuals (n=23) had 18-fold increased titers. Delta breakthrough infections (n=39) had 57-fold and 3.1-fold titers whereas Omicron breakthrough infections (n=14) had 5.8-fold and 0.32-fold titers compared to uninfected non-boosted and boosted individuals, respectively. The difference in titers (p=0.049) was related to a higher proportion of moderate to severe infections in the Delta cohort (p=0.014). Correlation of neutralizing and spike quantitative antibody titers was decreased with Delta or Omicron compared to WT. Neutralizing antibodies in Delta and Omicron breakthrough infections increase overall, but the relative magnitude of increase is greater in more clinically severe infection and against the specific infecting variant.
Licença
cc_by_nc_nd
Texto completo: 1 Coleções: 09-preprints Base de dados: PREPRINT-MEDRXIV Tipo de estudo: Cohort_studies / Observational_studies / Prognostic_studies Idioma: En Ano de publicação: 2022 Tipo de documento: Preprint
Texto completo: 1 Coleções: 09-preprints Base de dados: PREPRINT-MEDRXIV Tipo de estudo: Cohort_studies / Observational_studies / Prognostic_studies Idioma: En Ano de publicação: 2022 Tipo de documento: Preprint